Inflammation Research

, Volume 67, Issue 2, pp 117–127 | Cite as

Astragaloside IV attenuates orbital inflammation in Graves’ orbitopathy through suppression of autophagy

  • Hong Li
  • Yali Zhang
  • Jie Min
  • Long Gao
  • Ren Zhang
  • Yucheng Yang
Original Research Paper
  • 125 Downloads

Abstract

Introduction

Graves’ orbitopathy (GO) is an autoimmune inflammatory disorder affecting the orbit around the eye. Astragaloside IV (AS-VI) is the main active ingredient of the Chinese herbal medicine Huangqi (Radix Astragali Mongolici). AS-IV exhibits antioxidant and anti-inflammatory properties, and shows therapeutic potential in a number of ischemic and inflammatory diseases; however, its pharmaceutical activities in GO remain undefined.

Materials and methods

In this study, we investigated the effects of AS-IV on interleukin (IL)-1β-induced orbital fibroblast inflammation in vitro and GO orbital inflammation and ocular histopathological changes in vivo, as well as the underlying mechanisms responsible for these effects.

Results and conclusion

The results show that IL-1β increased mRNA expression of the inflammatory cytokines IL-6, IL-8, TNF-α, and MCP-1 in cultured orbital fibroblasts. This IL-1β-induced inflammation was accompanied by increased autophagic activity as reflected in increased Beclin-1 and Agt-5 expression, as well as LC3-I to LC3-II conversion. Pretreatment with the autophagy inhibitors 3-MA and bafilomycin A1, or silencing of autophagy-related proteins Beclin-1 and Atg-5, prevented IL-1β-induced orbital fibroblast inflammation, while pretreatment with the autophagy activator rapamycin had the opposite effects. These data suggested that autophagy was involved in GO orbital inflammation. AS-IV treatment significantly decreased IL-1β-induced inflammatory cytokine production in orbital fibroblasts in vitro and attenuated GO orbital inflammation, fat accumulation, collagen deposition, and macrophage infiltration in vivo. These in vitro and in vivo protective effects of AS-IV against GO were accompanied by decreased autophagic activities in orbital fibroblasts and GO orbital tissues, respectively. Collectively, our findings suggested that AS-IV protects against GO through suppression of autophagy. Thus, AS-IV may have preventive benefits for GO.

Keywords

Graves’ orbitopathy Inflammation Astragaloside IV Autophagy Fibroblast 

Notes

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant no. 81373617, 81072793, 30772800), Shanghai Committee of Science and Technology Research Projects (Grant no. 15401930400).

Compliance with ethical standards

Ethical approval

All animals were handled in accordance with the Guide for the Care and Use of Laboratory Animals. All animal experiments were approved by the Longhua Hospital Ethics Committee of China.

Conflict of interest

The authors declare that there were no conflicts of interest related to this study.

Supplementary material

11_2017_1100_MOESM1_ESM.doc (16 kb)
Supplementary material 1 (DOC 16 KB)
11_2017_1100_MOESM2_ESM.tif (2.4 mb)
Supplementary material 2 (TIF 2430 KB)
11_2017_1100_MOESM3_ESM.doc (16 kb)
Supplementary material 3 (DOC 16 KB)

References

  1. 1.
    Burch HB, Cooper DS. Management of graves disease: a review. JAMA. 2015;314:2544–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Smith TJ. Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33:414–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94:2708–16.CrossRefPubMedGoogle Scholar
  5. 5.
    Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Yoon JS, Lee HJ, Chae MK, Lee EJ. Autophagy is involved in the initiation and progression of Graves’ orbitopathy. Thyroid. 2015;25:445–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Tian YQ, Ding P, Yan XH, Hu WJ. [Discussion on quality control of preparations with cortex moutan in volume I pharmacopoeia of People’s Republic of China (2005 edition)]. Zhongguo Zhong Yao Za Zhi. 2008;33:339–41.PubMedGoogle Scholar
  8. 8.
    Ren S, Zhang H, Mu Y, Sun M, Liu P. Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med. 2013;33:413–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Hu JY, Han J, Chu ZG, Song HP, Zhang DX, Zhang Q, et al. Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels. Clin Exp Pharmacol Physiol. 2009;36:351–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Huang XP, Ding H, Lu JD, Tang YH, Deng BX, Deng CQ. Effects of the combination of the main active components of astragalus and panax notoginseng on inflammation and apoptosis of nerve cell after cerebral ischemia-reperfusion. Am J Chin Med. 2015;43:1419–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang B, Chen MZ. Astragaloside IV possesses antiarthritic effect by preventing interleukin 1beta-induced joint inflammation and cartilage damage. Arch Pharm Res. 2014;37:793–802.CrossRefPubMedGoogle Scholar
  12. 12.
    Xu H, Wang CY, Zhang HN, Lv CY, Wang YZ. Astragaloside IV suppresses inflammatory mediator production in synoviocytes and collageninduced arthritic rats. Mol Med Rep. 2016;13:3289–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111:1897–904.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol. 2013;15:741–50.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal. 2011;14:2201–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol. 2008;445:77–88.CrossRefPubMedGoogle Scholar
  17. 17.
    Lapaquette P, Guzzo J, Bretillon L, Bringer MA. Cellular and molecular connections between autophagy and inflammation. Mediators Inflamm. 2015;2015:398483.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Shibutani ST, Saitoh T, Nowag H, Munz C, Yoshimori T. Autophagy and autophagy-related proteins in the immune system. Nat Immunol. 2015;16:1014–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Yang Z, Goronzy JJ, Weyand CM. Autophagy in autoimmune disease. J Mol Med (Berl). 2015;93:707–17.CrossRefGoogle Scholar
  20. 20.
    Liu JN, Suh DH, Trinh HK, Chwae YJ, Park HS, Shin YS. The role of autophagy in allergic inflammation: a new target for severe asthma. Exp Mol Med. 2016;48:e243.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Marique L, Senou M, Craps J, Delaigle A, Van Regemorter E, Werion A, et al. Oxidative stress and upregulation of antioxidant proteins, including adiponectin, in extraocular muscular cells, orbital adipocytes, and thyrocytes in Graves’ disease associated with orbitopathy. Thyroid. 2015;25:1033–42.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Hong Li
    • 1
  • Yali Zhang
    • 2
  • Jie Min
    • 1
  • Long Gao
    • 1
  • Ren Zhang
    • 1
  • Yucheng Yang
    • 1
  1. 1.Department of EndocrinologyShanghai University of Traditional Chinese Medicine Longhua Affiliated HospitalShanghaiPeople’s Republic of China
  2. 2.Institute of Spleen and Stomach DiseaseShanghai University of Traditional Chinese Medicine Longhua Affiliated HospitalShanghaiPeople’s Republic of China

Personalised recommendations